Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in Western cancer patients. (February 2017) - Kwakman, R.J.; Baars, A.; Boot, H.; Pruijt, H.; Winther, S.; Pfeiffer, P.; Punt, C.